This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Antibiotic prophylaxis after intravitreal injections

Antibiotic prophylaxis after intravitreal injections
Reviewed by Brian Ang

1 June 2014 | Brian Ang | EYE - General

The use of topical antibiotics as prophylaxis after intravitreal injections is a contentious issue, especially now with increasing use of intravitreal anti-VEGF agents. In the Wills Eye Institute, prior to May 2011, all patients undergoing intravitreal injections in the office setting routinely received post-injection topical antibiotics four times daily for four days. However, the practice of post-injection antibiotics was discontinued practice-wide from September 2011 onwards. Apart from the cessation of post-injection antibiotics, there were no other changes to the technique of preparing for and administering the injections (with a 30- or 31-gauge needle). Topical 5% povidone iodine was applied pre-injection, but sterile draping and eyelash preparation were not used. The authors retrospectively compared the incidence of endophthalmitis following intravitreal injections during and after the post-injection topical antibiotic period. During the 28-month post-injection topical antibiotic period studied, 57,654 injections were administered with 28 cases of suspected endophthalmitis (0.049%) and 10 culture-positive endophthalmitis (0.017%). During the nine month period when post-injection topical antibiotics were discontinued, 34,900 injections were administered with 11 cases of suspected endophthalmitis (0.032%) and four culture-positive endophthalmitis (0.011%). The difference in endophthalmitis rates between the two groups was not statistically significant. This is the largest reported series of intravitreal injections so far, and the results are very compelling in demonstrating that post-injection topical antibiotics do not reduce the risk of endophthalmitis and in fact may even increase the risk of endophthalmitis. The evidence is clear that there is no role for routine post-injection antibiotic prophylaxis.

The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection.
Storey P, Dollin M, Pitcher J, et al.
OPHTHALMOLOGY
2014;121:283-9.
Share This
CONTRIBUTOR
Brian Ang

Royal Victorian Eye and Ear Hospital, Melbourne, Australia

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency